Prognostic value of intratumoral carbonic anhydrase IX expression in testicular germ cell tumors

KATARINA KALAVSKA1-3*, ZUZANA CIERNA4*, MICHAL CHOVANEČ2,5, MARTINA TAKACOVÁ6, DANIELA SVETOVA1-2, VIERA MISKOVÁ7,8, JANA OBERTOVA9, PATRIK PALACKÁ5, JAN RAJEC5, ZUZANA SYCOVA-MILA5, KATARINA MACHALEKOVÁ9, KAROL KAJO9, STANISLAV SPANIK7,8, JOZEF MARDIAK1,5, PAVEL BABAL4, SILVIA PASTOREKOVÁ6 and MICHAL MEGO1,2,5

1Translational Research Unit, Faculty of Medicine, Comenius University, 833 10 Bratislava; 2Department of Oncology, National Cancer Institute, 833 10 Bratislava; 3Cancer Research Institute, Biomedical Research Center, Slovak Academy of Sciences, 845 05 Bratislava; 4Department of Pathology, Faculty of Medicine, Comenius University, 811 08 Bratislava; 5Second Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute, 833 10 Bratislava; 6Institute of Virology, Biomedical Research Center, Slovak Academy of Sciences, 845 05 Bratislava; 7First Department of Oncology, Faculty of Medicine, Comenius University and St. Elisabeth Cancer Institute; 8Department of Oncology, St. Elizabeth Cancer Institute, 812 50 Bratislava; 9Department of Pathology, Slovak Medical University, 833 03 Bratislava, Slovak Republic

Received May 27, 2016; Accepted August 26, 2016

DOI: 10.3892/ol.2017.5745

Abstract. Testicular germ cell tumors (TGCTs) represent a highly curable malignancy, however a small proportion of patients fails to be cured with cisplatin-based chemotherapy. Carbonic anhydrase IX (CA IX) is upregulated by hypoxia in several cancer types and correlates with a poor prognosis. The present translational study evaluated expression and prognostic value of CA IX in TGCTs. Surgical specimens from 228 patients with TGCTs were processed by the tissue microarray method and subjected to immunohistochemistry with the M75 monoclonal antibody. CA IX expression was evaluated in tumors vs. adjacent normal testicular tissues and correlated with clinicopathological characteristics and clinical outcome. CA IX expression was detected in 62 (30.2%) of TGCTs compared to 0 (0%) of normal tissue adjacent to testicular tumor (P<0.001). The highest frequency of the CA IX expression was detected in teratoma (39.0%), followed by seminoma (22.7%), yolk sac tumor (22.2%), embryonal carcinoma (11.9%) and choriocarcinoma (7.7%). None of germ cell neoplasias in situ (GCNIS) exhibited CA IX expression. Patients without the CA IX tumor expression showed significantly better progression-free survival, but not overall survival, compared to patients with the CA IX expression [hazard ratio (HR), 0.57; 95% CI, 0.32-1.02; P=0.037 and HR, 0.58; 95% CI, 0.29-1.16; P=0.088, respectively]. There was no significant correlation between the CA IX expression and clinicopathological variables. The intratumoral CA IX expression can serve as a prognostic marker in the TGCT patients. These results suggest that activation of the hypoxia-induced pathways may be important in the treatment failure in TGCTs patients.

Introduction

Testicular germ cell tumors (TGCTs) belong to the most common malignancies among men aged between 20-40 years (1,2). TGCTs are highly curable malignancies and even the majority of metastatic patients may expect to be cured with the first-line cisplatin-based chemotherapy (3,4). Despite the high curative rate, there are ~20-30% of patients who fail to achieve a durable complete remission (3). Salvage chemotherapy based on the standard cisplatin dose and previously non-utilized chemotherapeutic agents or high-dose salvage chemotherapy with autologous stem cell transplantation can induce durable remission in 20-60% of patients with relapsed disease (3,5,6). Current treatment strategies in cisplatin-refractory and relapsed TGCTs patients are insufficient. Thus, novel treatment strategies, including drugs with antitumor activity, as well as novel biomarkers as effective tools for better stratification of patients are required.

The process of tumor development is characterized by rapid proliferation of cancer cells and the expansion of tumor tissue associated with hypoxia in the tumor microenvironment (7). Carbonic anhydrase IX (CA IX) is a zinc metalloenzyme, which catalyzes a reversible hydration of carbon dioxide to

Correspondence to: Dr Michal Mego, Second Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute, Klenova 1, 833 10 Bratislava, Slovak Republic

E-mail: misomego@gmail.com

*Contributed equally

Key words: carbonic anhydrate IX, testicular germ cell tumors, prognostic marker
bicarbonate and a proton, and participates in pH regulation, in addition to cell adhesion-migration-invasion (8). Thus, CA IX, localized in the plasma membrane, enables tumor cells to maintain a normal intracellular pH under hypoxic conditions, while concurrently acidifying the extracellular microenvironment. The increased expression of CA IX promotes invasion and metastasis and is associated with treatment resistance in several types of cancer (9-12). Hypoxia and CA IX have been also linked with cancer stem cell properties (13-15). Furthermore, inhibition of angiogenesis is able to generate a hypoxic tumor microenvironment, thereby increasing the population of breast cancer stem cells (16). Thus, an increased proportion of circulating tumor cells derived from tumors that grow under hypoxic conditions may contribute to a poor treatment outcome and increased resistance to chemotherapy (17). Since cancer stem cells in TGCTs resemble embryonic stem cells (9,18), we propose that CA IX, as a mediator of tumor responses to hypoxia, may be involved in the pathogenesis of TGCTs.

The aim of the present translational study was to investigate the CA IX protein expression in TGCTs and to evaluate its potential prognostic role in these patients. We examined the CA IX expression in all histological subtypes of TGCTs, as well as in GCNIS (germ cell neoplasia in situ) specimens and in the normal testicular tissue adjacent to testicular tumor.

Patients and methods

Patients. The present translational study (Protocol IZLO1, Chair: M. Mego) involved 228 patients with TGCTs treated from January 2000 to September 2013 in the National Cancer Institute of Slovakia, Bratislava, Slovakia and St. Elisabeth Cancer Institute, Bratislava, Slovakia, with available paraffin embedded tumor tissue specimen and sufficient follow-up clinical data. Patients with a concurrent malignancy other than non-melanoma skin cancer in the previous 5 years were excluded from the study. In all patients, data regarding age, tumor histological subtype, clinical stage and type and number of metastatic lesions were recorded and compared with the CA IX expression. The Institutional Review Board of the National Cancer Institute, Bratislava, Slovakia approved this retrospective study and a waiver of patient consent was granted.

Tumor pathology. Pathological review was conducted at the Department of Pathology, Faculty of Medicine, Comenius University, Bratislava, Slovakia by two pathologists (Z.C. and P.B.) associated with the study.

Diagnosis and tissue samples. Tumor tissue, samples with germ cell neoplasias in situ (GCNIS), and normal testicular tissue were evaluated in all cases, when available. The present study included tumor specimens from 228 patients prior to the administration of systemic therapy. Primary testicular tumor specimens were obtained in 205 (89.9%) patients. Biopsies of metastatic sites were available in 23 (10.1%) cases.

The TGCTs were classified according to the World Health Organization criteria (19). Since the normal testicular biopsies from non-cancer patients were not available for our analysis, normal tissue adjacent to testicular tumor was used for evaluation of CA IX expression, as described in previous studies (20-22).

Tissue microarray construction. According to tumor histology, one or two representative tumor areas from each histological subtype of germ cell tumor (from 1-6 cores from each tumor) were identified on haematoxylin and eosin stained sections. Samples from normal testicular tissue and germ cell neoplasia in situ were also marked, if present. Sections were matched to their corresponding wax blocks (the donor blocks), and 3-mm diameter cores of the tumor were removed from these donor blocks with the multipurpose sampling tool Harris Uni-Core (Sigma-Aldrich, Steinheim, Germany) and inserted into the recipient master block. The recipient block was cut into 5-μm sections that were transferred to coated slides.

Immunohistochemical staining. Deparaffinized slides were rehydrated in phosphate buffered saline solution (10 mM, pH 7.2). The tissue epitopes were demasked using the automated water bath heating process in Dako PT Link (Dako, Glostrup, Denmark); the slides were incubated in TRIS-EDTA retrieval solution (10 mM TRIS, 1 mM EDTA pH 9.0) at 98°C for 20 min. This step was introduced because of low intensity of staining when the standard CA IX immunohistochemical staining protocol was used (23). Increasing the concentration, nor the extension of incubation time with the M75 primary antibody, did improve the staining result, however, pretreatment with TRIS-EDTA substantially strengthened the reaction signal. The slides were subsequently incubated for 1 h at room temperature with the monoclonal antibody M75 against the N-terminal domain of the human CA IX protein (23,24) diluted 1:100 in Dako REAL antibody diluent (Dako, Glostrup, Denmark) and immunostained using anti-mouse/anti-rabbit immune-peroxidase polymer (EnVision FLEX/HRP, Dako, Glostrup, Denmark) for 30 min at room temperature, according to the manufacturer's instructions. The reaction was visualized with a diaminobenzidine substrate-chromogen solution (DAB, Dako Cytomation, Denmark) for 5 min, and slides were counter-stained with haematoxylin. The trophoblast staining in human placenta served as positive control. Additional testicular tumors specimens stained with omission of the primary antibody served as negative control. Additional testicular tumors specimens stained with omission of the primary antibody served as negative control.

Immunohistochemistry scoring. Two observers (Z.C. and P.B.) who were blinded to clinicopathological data conducted an independent analysis of the tumor cores. In cases of disagreement, the result was reached by consensus. CA IX expression was stratified as negative or positive (any staining).

Statistical analysis. The patients’ characteristics were summarized as mean or median (range) values for continuous variables and frequency (percentage) for categorical variables, respectively. Statistical analysis was performed using non-parametric tests as the distribution of the CA IX expression was significantly different from the normal distribution (Shapiro-Wilk test). Analyses of differences in distributions of CA IX expression between the two groups of patients were performed using the Mann-Whitney U test, whereas Fisher's exact test or the χ2 test were used when CA IX expression was categorized as ‘absent’ or ‘present’ according to the aforementioned
criteria. Median follow-up period was calculated as a median observation time of all patients and of those still alive at the time of their last follow-up. Progression-free survival (PFS) was calculated from the date of the starting treatment with systemic therapy to the date of progression or death or the date of the last adequate follow-up. Overall survival (OS) was calculated from the date of starting treatment with systemic therapy to the date of death or last follow-up. PFS and OS were estimated using the Kaplan-Meier product limit method and were compared with the log-rank test. A multivariate Cox proportional hazards model for PFS and OS was used to assess differences in outcome on the basis of the CA IX expression in primary tumor and/or biopsy of metastatic site and prognosis according to the IGCCCG (International Germ Cell Collaborative Group) criteria (1997) (19). All presented P-values were two sided. Values of P<0.05 were considered to indicate a statistically significant difference. Statistical analyses were performed using NCSS 2007 software developed by Hintze J (2007) (NCSS, LLC, Kaysville, UT, USA) (25).

Results

Patient characteristics. Patients characteristics are summarized in Table I. The mean age of patients enrolled into this study was 30 years (range, 16-67 years). The majority of patients had non-seminomatous primary testicular tumor, and had good prognosis according to the IGCCCG criteria. All patients were treated with cisplatin-based chemotherapy. No extragonadal germ cell tumors were included.

In total, 228 patient specimens were analyzed for CA IX expression using immunohistochemical analysis. CA IX staining was evaluated in 321 tumor specimens from primary testicular tumors (205 patients, Table II), in 23 specimens from metastatic sites sampled post chemotherapy, and in 107 adjacent normal testicular tissues. GCNIS adjacent to testicular tumor was present in 76 patients.

The analyzed cohort of primary testicular tumors included 49 pure seminomas, 79 non-seminomas (57 embryonal carcinomas, 12 yolk sac tumors, 9 teratomas, 1 choriocarcinoma) and 76 mixed germ cell tumors (Table III). Six cases of seminomas were clinically considered as non-seminomas based on positivity of alpha-fetoprotein.

Association between CA IX expression and patients/tumor characteristics. CA IX staining of various TGCTs histological subtypes and normal tissue adjacent to testicular tumor is presented in Fig. 1. Whereas normal testicular tissue adjacent to testicular tumor did not show any CA IX staining, CA IX expression was detected in all histological subtypes of TGCTs (Table II). The highest frequency of the CA IX expression was in teratoma samples, with decreasing trend in seminoma, embryonal carcinoma, yolk sac tumor and choriocarcinoma. In choriocarcinomas, the CA IX staining was observed only in one (7.7%) specimen, while no CA IX expression was observed in GCNIS. CA IX expression was detected in 17 seminomas (22.7), 14 embryonal carcinomas (11.9), 8 yolk sac tumors (22.2) and 23 teratomas (39.0) compared to 0 (0.0) of normal testicular tissue adjacent to testicular tumor (P<0.001; Table II).

The CA IX staining pattern was largely focal in the tumor tissue, with prevailing membrane positivity in seminomas and embryonal carcinomas and cytoplasmic staining in the other histological subtypes. Mesenchymal cells in teratomas and in the tumor stroma exhibited focal positivity, the intercellular matrix was negative (Fig. 1). Areas of cells neighboring with necrosis did not show increased CA IX expression.

In addition, we analyzed the relationship between the CA IX expression in primary tumors and clinicopathological features (Table IV). We did not find any significant association of the CA IX expression in primary tumors with patients/tumor characteristic, such as tumor histology, IGCCCG risk group, number and localization of metastatic sites and S-stage (Table V). The Spearman's test did not show any significant correlation between the intratumoral CA IX expression and LDH level (Spearman's correlation index, P=0.216).

Prognostic value of CA IX. The median follow-up time was 82.3 months (0.3-289.1 months) for all 228 patients and 92.6 months (14.2-289.1 months) for patients still alive. To the
date of last follow-up, 56 patients (24.6%) experienced disease progression and 38 patients (16.7%) had succumbed. The estimated 2-year and 5-year PFS survival was 80.3% (95% CI, 75.1-85.4%) and 78.3% (95% CI, 72.9-83.7%), while the estimated 2-year and 5-year OS survival was 90.3% (95% CI, 86.5-94.2%) and 85.1% (95% CI, 80.4-89.8%), respectively.

In univariate analysis, patients without CA IX expression in analyzed tumor specimens had significantly better PFS, in contrast to patients with the CA IX expression [hazard ratio (HR), 0.57; 95% CI, 0.32-1.02; P=0.0365; Fig. 2]. Moreover, there was a trend for association between the CA IX expression and OS in this patients’ cohort (HR, 0.58; 95% CI, 0.29-1.16; P=0.0876; Fig. 3). Multivariate analysis revealed that CA IX

| Table II. CA IX expression in different histologic subtypes of the primary germ cell tumors (n=205). |
|---------------------------------------------------------------|
| CA IX expression                                               |
| | No. | %   | No. | %   | P-value |
|---------------------------------------------------------------|
| Healthy testis                                                |
| 107                                                                 |
| 107 | 100.0 | 0 | 0.0 | N/A |
| Testicular germ cell tumors                                   |
| 205                                                                 |
| 143 | 69.8 | 62 | 30.2 | <0.001 |
| Seminoma                                                      |
| 75                                                                 |
| 58 | 77.3 | 17 | 22.7 | <0.001 |
| Embryonal carcinoma                                           |
| 118                                                                 |
| 104 | 88.1 | 14 | 11.9 | <0.001 |
| Yolk sac tumor                                                |
| 36                                                                 |
| 28 | 77.8 | 8 | 22.2 | <0.001 |
| Choriocarcinoma                                               |
| 13                                                                 |
| 12 | 92.3 | 1 | 7.7 | 0.11 |
| Teratoma                                                      |
| 59                                                                 |
| 36 | 61.0 | 23 | 39.0 | <0.001 |
| GCNIS                                                         |
| 76                                                                 |
| 76 | 100.0 | 0 | 0.0 | N/A |

GCNIS, germ cell neoplasia in situ; CA IX, carbonic anhydrase IX.

| Table III. Composition of mixed testicular germ cell tumors (n=76). |
|---------------------------------------------------------------|
| No. of patients | Histological subtype       |
| 22               | EC/TER                      |
| 15               | EC/SEM                      |
| 6                | EC/YST/TER                  |
| 6                | YST/TER                     |
| 5                | EC/YST                      |
| 4                | EC/ChC/TER                  |
| 4                | SEM/TER                     |
| 3                | EC/SEM/TER                  |
| 3                | EC/ChC                      |
| 3                | YST/ChC/TER                 |
| 1                | EC/SEM/YST                  |
| 1                | EC/SEM/YST/TER              |
| 1                | SEM/YST                     |
| 1                | EC/SEM/ChC                  |
| 1                | YST/ChC                     |

EC, embryonal carcinoma; SEM, seminoma; YST, yolk sac tumour; ChC, choriocarcinoma; TER, teratoma.

Figure 1. Immunohistochemical detection of CA IX expression in testicular germ cell tumors. (A) Seminoma showed focal moderate membrane CA IX positivity (brown). (B) Yolk sac tumor with focal strong cytoplasmic CA IX positivity. (C) Embryonal carcinoma with focal strong cytoplasmic CA IX positivity. (D) Mature teratoma with strong cytoplasmic CA IX positivity in epithelial component and negativity in mesenchymal component. Magnification, upper x40, lower x400. CA IX, carbonic anhydrase IX.
expression in tumor tissues was associated with PFS independently of the IGCCCG risk group, however this correlation did not reach statistical significance (P=0.0682). Moreover, no significant association was shown between the IGCCCG risk group and the CA IX expression as an independent prognostic factor for overall survival (Table V).

Therefore, exploratory subgroup analysis was performed to reveal a potential subgroup-related prognostic value of CA IX (Table VI). This analysis demonstrated that the tumor CA IX expression correlated with the worse PFS in non-seminoma patients, patients with one or more metastatic lesions and patients with retroperitoneal lymph node metastases. Furthermore, the absence of the CA IX expression in primary tumors was significantly associated with better PFS in patients without lung, brain and non-pulmonary visceral metastases.

Discussion

Carbonic anhydrase IX (CA IX) is a hypoxia-inducible enzyme that is important in cancer development, progression, acidification and metastasis (8). There is increasing evidence that overexpression of CA IX in a variety of cancers correlates with an unfavorable outcome, and is related to a decrease in the progression free survival following successful therapy. Therefore, it is considered as a surrogate tumor biomarker (26).
The present translational study demonstrated significantly increased CA IX expression in TGCTs, in contrast to its absence in normal testicular tissue adjacent to germ cell tumors. CA IX expression was detected in all histological subtypes, with the highest expression in teratomas. These findings can be explained by the mesodermal origin of all CA IX expressing cells. Moreover, our results are supported by the detection of CA IX expression in the flat surface epithelium (modified mesothelium) of all male and female genital organs (27). Only one of thirteen choriocarcinoma specimens was positive in CA IX staining. This result is consistent with the study of Donato et al (28), where choriocarcinoma tumors were predominantly negative in CA IX. In contrast to the results published by Donato et al (28), the present study detected CA IX expression not only in teratomas and embryonal carcinomas, but also in seminomas and in yolk sac tumors. On the other hand we identified no CA IX expression in germ cell neoplasia in situ. GCNIS represents a precursor lesion for invasive TGCT of the adult testis (29). Thus, we may suppose that CA IX expression does not belong to early events in the pathogenesis of TGCTs. We also failed to detect any significant association between the CA IX expression and the patients/tumor characteristics. However, our data indicated the value of CA IX in the prognosis of progression-free survival, since CA IX expression in analyzed patients tumor specimens correlated with the significantly worse PFS. These findings are in agreement with previous reports on the prognostic value of CA IX in the wide variety of human carcinomas, including upper gastrointestinal cancer, breast cancer, ovarian and cervical cancer, nasopharyngeal cancer, lung and rectal cancer (30-36). The relationship between the CA IX expression and progression-free survival in TGCT patients was confirmed by the subgroup analysis of non-seminoma patients, patients with one or more metastatic site as well as patients with retroperitoneal lymph node metastases. Moreover, the analysis of patients without lung, brain and non-pulmonary visceral metastases showed a similar association. On the other hand, we did not observe any association between the CA IX expression and unfavorable outcome in patients with brain metastases, non-pulmonary visceral metastases and in patients with S-stage 3. It is therefore possible that the poor prognosis of these groups of patients is related to other pathways than that driven by hypoxia. Based on these findings, we propose that CA IX expression, mainly in patients with metastatic

Table V. Multivariate analysis of the potential prognostic value of CA IX.

| Variable                                           | Progression free survival | Overall survival |
|----------------------------------------------------|---------------------------|-----------------|
|                                                    | HR (95% CI)                | P-value         | HR (95% CI) | P-value |
| CA IX expression in primary tumor high vs. low     | 1.650 (0.963-2.826)       | 0.068           | 1.613 (0.844-3.080) | 0.148   |
| IGCCCG risk group poor vs. good/intermediate prognosis | 5.260 (3.005-9.209)       | <0.001          | 8.282 (4.286-16.005) | <0.001   |

CA IX, carbonic anhydrase IX; IGCCCG, international germ cell consensus classification group; HR, hazard ratio; CI, confidence interval.
disease but without high-risk features (specifically, patients without brain and non-pulmonary visceral metastases and/or S-stage 3) may serve as prognostic marker of inferior outcome. This suggestion is also supported by the observation, that the hypoxic microenvironment plays a role in inferior outcome and chemoresistance due to increased burden of circulating tumor cells (16). Experimental data suggest that the tumor cells over-express CA IX in order to maintain the intracellular pH and thus preserve their survival in hypoxia (37). The acidification of extracellular space mediated by this mechanism contributes to tumor cell invasion, development of metastases and therefore to worse progression-free survival (38,39). The study has some limitations, including the relative under-representation of choriocarcinoma and yolk sac tumor and the selection of tissue samples into the tissue microarray. For this reason we performed whole tissue section immunohistochemical staining of several TGCT cases, and identified corresponding staining pattern with that in the tissue array. Notably, the TRIS-EDTA pretreatment of the slides considerably increased the sensitivity of CA IX expression detection in the studied tumor specimens.

In conclusion, the present translational study demonstrated significant overexpression of CA IX in TGCTs when compared to normal testicular tissue. We detected for the first time an association between CA IX expression in primary tumor tissue and worse progression-free survival in patients with TGCTs. Higher CA IX expression correlating with inferior outcome was found predominantly in patients with metastatic disease. These results suggest that CA IX expression may serve as an important predictive factor associated with disease recurrence.

Table VI. Prognostic value of CA IX as an independent indicator in different patient subgroups.

| Variable                                      | No. | PFS HR (95% CI) | P-value | OS HR (95% CI) | P-value |
|-----------------------------------------------|-----|----------------|---------|----------------|---------|
| **Histology**                                 |     |                |         |                |         |
| Seminoma                                      | 44  | 2.46 (0.45-13.48) | 0.396   | 1.00 (0.09-11.00) | 0.997   |
| Non-seminoma                                  | 184 | 0.47 (0.25-0.87)  | **0.006** | 0.54 (0.26-1.12) | 0.067   |
| **IGCCCG group**                              |     |                |         |                |         |
| Good prognosis                                | 173 | 0.68 (0.29-1.62)  | 0.342   | 0.56 (0.16-1.94) | 0.305   |
| Intermediate prognosis                        | 25  | 0.49 (0.14-1.72)  | 0.258   | 0.88 (0.22-3.53) | 0.857   |
| Poor prognosis                                 | 30  | 0.73 (0.29-1.88)  | 0.499   | 0.73 (0.27-1.99) | 0.518   |
| **Number of metastatic sites**                |     |                |         |                |         |
| 0                                             | 64  | 0.79 (0.14-4.46)  | 0.756   | 0.43 (0.05-3.53) | 0.317   |
| ≥1                                            | 164 | 0.50 (0.27-0.94)  | **0.013** | 0.56 (0.27-1.19) | 0.099   |
| **Reroperitoneal LN metastases**              |     |                |         |                |         |
| Present                                       | 159 | 0.49 (0.26-0.94)  | **0.014** | 0.58 (0.27-1.24) | 0.120   |
| Absent                                        | 69  | 0.65 (0.14-3.05)  | 0.536   | 0.33 (0.05-2.11) | 0.141   |
| **Mediastinal LN metastases**                 |     |                |         |                |         |
| Present                                       | 23  | 0.43 (0.13-1.41)  | 0.161   | 0.48 (0.12-1.94) | 0.303   |
| Absent                                        | 205 | 0.68 (0.35-1.31)  | 0.210   | 0.60 (0.26-1.37) | 0.1785  |
| **Lung metastases**                           |     |                |         |                |         |
| Present                                       | 52  | 0.82 (0.35-1.92)  | 0.636   | 0.69 (0.28-1.68) | 0.379   |
| Absent                                        | 176 | 0.48 (0.22-1.05)  | **0.035** | 0.50 (0.17-1.49) | 0.162   |
| **Liver metastases**                          |     |                |         |                |         |
| Present                                       | 12  | 0.30 (0.05-2.01)  | 0.115   | 0.32 (0.05-2.05) | 0.130   |
| Absent                                        | 216 | 0.60 (0.33-1.12)  | 0.076   | 0.62 (0.29-1.32) | 0.176   |
| **Brain metastases**                          |     |                |         |                |         |
| Present                                       | 3   | NA             | NA      | NA             | NA      |
| Absent                                        | 225 | 0.54 (0.30-0.98)  | **0.024** | 0.53 (0.26-1.08) | 0.052   |
| **Non-pulmonary visceral metastases**         |     |                |         |                |         |
| Present                                       | 16  | 0.52 (0.10-2.64)  | 0.355   | 0.53 (0.11-2.68) | 0.377   |
| Absent                                        | 217 | 0.56 (0.30-1.04)  | **0.041** | 0.55 (0.25-1.21) | 0.099   |
| **S-stage**                                   |     |                |         |                |         |
| 0-II                                          | 206 | 0.57 (0.29-1.12)  | 0.070   | 0.61 (0.26-1.45) | 0.224   |
| III                                           | 22  | 0.62 (0.20-1.91)  | 0.368   | 0.51 (0.16-1.67) | 0.219   |

P-values in bold indicate statistically significant differences. CA IX, carbonic anhydrase IX; IGCCCG, international germ cell consensus classification group; HR, hazard ratio; CI, confidence interval; PFS, progression free survival; OS, overall survival; LN, lymph node.
and poor progression-free survival time in patients with advanced testicular cancer.

Acknowledgements

The authors of the present study would like to acknowledge our collaborators: Dr Antol M from the Department of Pathology, Regional Hospital and Health Centre, Levoča, Slovakia, Dr Benko J from the Department of Pathology, University Hospital in Nové Zámky, Slovakia, Dr Danis D and Dr Galbavy S from the Department of Pathology, Slovak Medical University, Bratislava, Slovakia, Dr Durcansky D from the Department of Pathology, Regional Hospital and Health Centre, Prievidza, Slovakia, Dr Fiala P from the Department of Pathology, Faculty of Medicine, Pavol Jozef Šafárik University in Košice, Slovakia, Dr Gogora M from the Department of Pathology, Regional Hospital and Health Centre, Ilava, Slovakia, Dr Hudcovsky P from the Department of Pathology, Regional Hospital and Health Centre, Šaľa, Slovakia, Dr Macuch J from the Department of Clinical Pathology, National Cancer Institute, Bratislava, Slovakia, Dr Martianovic P from the Department of Forensic Medicine, Faculty of Medicine, Comenius University, Bratislava, Slovakia, Dr Ondrias F from the Department of Pathology, University Hospital Bratislava, Ruzinov, Slovakia, Dr Plank L from the Department of Pathology, Comenius University, Jessenius Medical Faculty and Martin’s Faculty Hospital, Martin, Slovakia and Dr Svajdler M from the Department of Pathology, Louis Pasteur University Hospital in Kosice, Slovakia. We would like to acknowledge Mrs. Daniela Jantekova, from the Population Registry of Slovak Republic, Bratislava, Slovakia for help with updating the patient database, and Dr Maria Reckova, 2nd Department of Oncology, Faculty of Medicine, Comenius University, Bratislava, Slovakia for discussions and critical input. We would like to acknowledge Mrs. Zlatica Pekova from the Department of Pathology, Regional Hospital and Health Centre, Košice, Slovakia, Mr. Ludovit Gaspar from the Department of Pathology, Faculty of Medicine, Comenius University, Bratislava, Slovakia for excellent technical assistance. The present study was supported by the Slovak Research and Development Agency (Bratislava, Slovakia; grant no. VEGA-2/0108/16) and the Slovak Scientific Grant Agency (Bratislava, Slovakia; grant no. VEGA-2/0108/16).

References

1. Rijlaardsma MA and Looijenga LH: An oncofetal and developmental perspective on testicular germ cell cancer. Semin Cancer Biol 29: 59-74, 2014.
2. Trabert B, Chen J, Devesa SS, Bray F and McGlynn KA: International patterns and trends in testicular cancer incidence, overall and by histologic subtype, 1973-2007. Andrology 3: 4-12, 2015.
3. Feldman DR, Bosl GJ, Sheinfeld J and Motzer RJ: Medical treatment of advanced testicular cancer. JAMA 299: 672-684, 2008.
4. Voutsadakis IA: The chemosensitivity of testicular germ cell tumors. Cell Oncol (Dordr) 37: 79-94, 2014.
5. Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Buyyounouski MK, Carducci MA, Chang SS, Choueiri TK, Gupta S, et al: Testicular cancer. J Natl Compr Canc Netw 10: 502-535, 2012.
6. Mardiak J, Sálek T, Svoova-Milá Z, Obertová J, Hlavatá Z, Mego M, Recková M and Kozá K: Paclitaxel plus ifosfamide and cisplatin in second-line treatment of germ cell tumors: A phase II study. Neoplasma 52: 497-501, 2005.
7. Heddleston JM, Li Z, Lathia JD, Bao S, Hjelmeland AB and Rich JN: Hypoxia inducible factors in cancer stem cells. Br J Cancer 102: 789-795, 2010.
8. Pastorek J and Pastorekova S: Hypoxia-induced carbonic anhydrase IX as a target for cancer therapy: From biology to clinical use. Semin Cancer Biol 31: 52-64, 2015.
9. McIntyre A, Patiar S, Wigfield S, Li JL, Ledaki I, Turley H, Leek R, Snell C, Gatter K, Sly WS, et al: Carbonic anhydrase IX promotes tumor growth and necrosis in vivo and inhibition enhances anti-VEGF therapy. Clin Cancer Res 18: 3100-3111, 2012.
10. Jubb AM, Buffa FM and Harris AL: Assessment of tumour hypoxia for prediction of response to therapy and cancer prognosis. J Cell Mol Med 14: 18-29; 2010.
11. Tan EY, Yan M, Campo L, Han C, Takano E, Turley H, Candiloro I, Pezzella F, Gatter KC, Millar EK, et al: The key hypoxia regulated gene CA IX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy. Br J Cancer 100: 405-411, 2009.
12. Generali D, Fox SB, Berruti A, Brizzii MP, Campo L, Bonardi S, Wigfield SM, Bruzzi P, Bersiga A, Allevi G, et al: Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer. Endocr Relat Cancer 13: 921-930, 2006.
13. McCord AM, Jamal M, Williams ES, Camphausen K and Toftlon PJ: CD133+ glioblastoma stem-like cells are radiosensitive with a defective DNA damage response compared with established cell lines. Clin Cancer Res 15: 5145-5153, 2009.
14. Lock FE, McDonald PS, Lou Y, Serrano I, Chafe SC, Ostlund C, Aparicio S, Winum YJ, Supuran CT and Dedhar S: Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche. Oncogene 32: 5210-5219, 2013.
15. Ledaki I, McIntyre A, Wigfield S, Buffa M, McGowan S, Baban D, Li JL and Harris AL: Carbonic anhydrase IX induction defines a heterogenous cancer cell response to hypoxia and mediates stem cell-like properties and sensitivity to HDAC inhibition. Oncotarget 6: 9413-9427, 2015.
16. Conley SJ, Gheordunescu E, Kakarakia P, Newman B, Korkaya H, Heath AN, Clouthier SD and Wicha MS: Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci USA 109: 2784-2789, 2012.
17. Yeung TM, Gandhi SC and Bodmer WF: Hypoxia and lineage specification of cell line-derived colorectal cancer stem cells. Proc Natl Acad Sci USA 108: 4382-4387, 2011.
18. Sheikine Y, Genega E, Memamed J, Lee P, Reuter VE and YE H: Molecular genetics of testicular germ cell tumors. Am J Cancer Biol 2: 153-167, 2012.
19. Ulbricht TM, Amin MB, Balzer B, Berney DM, Epstein JI, Guo C, Idrees MT, Looijenga LHJ, Paner G, et al: Germ cell tumors. In: WHO Classification of tumours of the urinary system and male genital organs. Moch H, Humphrey PA, Reuter VE, Ulbricht TM (eds). IARC Press, Lyon, p185-258, 2016.
20. Barbagallo F, Paronetto MP, Franco R, Chieffi P, Dolci S, Fry AM, Geremia R and Sette C: Increased expression and nuclear localization of the centrosomal kinase Nek2 in human testicular seminomas. J Pathol 217: 431-441, 2009.
21. Ulisse S, Baldini E, Mottolese M, Sentinelli S, Gargiulo P, Valentina B, Sorrenti S, Di Benedetto M, Enzo A and D’Armiento M: Increased expression of urokinase plasminogen activator and its cognate receptor in human seminomas. BMC Cancer 10: 151, 2010.
22. Mezo M, Czernia Z, Svetlovits D, Macak D, Machalekova V, Chovanec M, Usakova V, Obertova J, Babal P and Mardiak J: PARP expression in germ cell tumors. J Clin Pathol 60: 607-612, 2013.
23. Takacova M, Bullova P, Simko V, Skvarkova L, Poturnajova M, Peklourovna L, Kubiova T, Kopacek J, et al: Expression pattern of carbonic anhydrase IX in medullary thyroid carcinoma supports a role for ret-mediated activation of the HIF pathway. Am J Pathol 184: 953-965, 2014.
24. Pastoreková S, Závadová Z, Kostál M, Babušková O and Závada J: A novel quencher agent, MaTl, is a two-component system. Virology 187: 620-626, 1992.
25. Hintze J: NCSS 2007. NCSS, LLC, Kaysville, UT, 2007.
26. Tafreshi NK, Lloyd MC, Bui MM, Gillies RJ and Morse DL: Carbonic anhydrase IX as an imaging and therapeutic target for tumors and metastases. Subcell Biochem 75: 221-254, 2014.

27. Liao SY, Lerman MI and Stanbridge EJ: Expression of transmembrane carbonic anhydrases, CA IX and CAXII, in human development. BMC Dev Biol 9: 22, 2009.

28. Donato DP, Johnson MT, Yang XJ and Zynger DL: Expression of carbonic anhydrase IX in genitourinary and adrenal tumours. Histopathology 59: 1229-1239, 2011.

29. van Echten J, Oosterhuis JW, Looijenga LH, van de Pol M, Wiersema J, te Meerman GJ, Sleijfer DT and de Jong B: No recurrent structural abnormalities apart from i(12p) in primary germ cell tumors of the adult testis. Gene Chromosomes Cancer 14: 133-144, 1995.

30. Loncaster JA, Harris AL, Davidson SE, Logue JP, Hunter RD, Wycoff CC, Pastorek J, Ratcliffe PJ, Stratford IJ and West CM: Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: Correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 61: 6394-6399, 2001.

31. Hui EP, Chan AT, Pezzella F, Turley H, To KF, Poon TC, Zee B, Mo F, Teo PM, Huang DP, et al: Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res 8: 2595-2604, 2002.

32. Driessen A, Landsay W, Pastoreková S, Moons J, Goelalz L, Haustermans K, Nafeux P, Penninckx F, Geboes K, Lerut T and Ectors N: Expression of carbonic anhydrase IX (CA IX), a hypoxia-related protein, rather than vascular-endothelial growth factor (VEGF), a pro-angiogenic factor, correlates with an extremely poor prognosis in esophageal and gastric adenocarcinomas. Ann Surg 243: 334-340, 2006.

33. Hynynen P, Vaskivuo L, Saarnio J, Haapasalo H, Kivelä J, Pastoreková S, Pastorek J, Waheed A, Sly WS, Puistola U and Parkkila S: Expression of transmembrane carbonic anhydrases IX and XII in ovarian tumors. Histopathology 49: 594-602, 2006.

34. Hussain SA, Rea DW and Palmer DH: Reply: Randomised studies with translational end points are required to further elucidate the prognostic and predictive value of CA IX. Br J Cancer 96: 1310, 2007.

35. Korkela E, Talviken K, Jaakkola PM, Minn H, Syrjänén K, Sundström J and Pyrhönen S: Reply: Expression of carbonic anhydrase IX suggests poor response to therapy in rectal cancer. Br J Cancer 101: 373, 2009.

36. Giatromanolaki A, Koukourakis MI, Sivridis E, Turley H, Talks K, Pezzella F, Gatter KC and Harris AL: Relation of hypoxia inducible factor 1alpha and 2alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer 85: 881-890, 2001.

37. Swietach P, Hulikova A, Vaughan-Jones RD and Harris AL: New insights into the physiological role of carbonic anhydrase IX in tumour pH regulation. Oncogene 29: 6509-6521, 2010.

38. Gatenby RA and Gillies RJ: Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4: 891-899, 2004.

39. Wojtkowiak JW, Verduzco D, Schramm KJ and Gillies RJ: Drug resistance and cellular adaptation to tumor acidic pH microenvironment. Mol Pharmacol 8: 2032-2038, 2011.